SNOA Stock Overview
Develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sonoma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$1.19 |
| 52 Week Low | US$0.12 |
| Beta | 1.37 |
| 11 Month Change | 3.66% |
| 3 Month Change | 46.34% |
| 1 Year Change | -80.59% |
| 33 Year Change | -97.08% |
| 5 Year Change | -97.05% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| SNOA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 11.8% | -1.2% | -0.06% |
| 1Y | -80.6% | 18.1% | 20.5% |
Return vs Industry: SNOA underperformed the US Pharmaceuticals industry which returned 18.1% over the past year.
Return vs Market: SNOA underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| SNOA volatility | |
|---|---|
| SNOA Average Weekly Movement | 24.6% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SNOA's share price has been volatile over the past 3 months.
Volatility Over Time: SNOA's weekly volatility has increased from 18% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10 | Amy Trombly | sonomapharma.com |
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
Sonoma Pharmaceuticals, Inc. Fundamentals Summary
| SNOA fundamental statistics | |
|---|---|
| Market cap | US$4.03m |
| Earnings (TTM) | -US$4.83m |
| Revenue (TTM) | US$12.74m |
0.3x
P/S Ratio-0.8x
P/E RatioIs SNOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNOA income statement (TTM) | |
|---|---|
| Revenue | US$12.74m |
| Cost of Revenue | US$7.99m |
| Gross Profit | US$4.75m |
| Other Expenses | US$9.58m |
| Earnings | -US$4.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 37.26% |
| Net Profit Margin | -37.97% |
| Debt/Equity Ratio | 5.3% |
How did SNOA perform over the long term?
See historical performance and comparison